XBI — SPDR® S&P® Biotech ETF
Data updated: 2026-09-11
XBI — SPDR® S&P® Biotech ETF. United States Small Cap Blend / Core Health Care Equity · $10.73B AUM. Holdings, fees, performance and SEC filings.
XBI Fund Overview
XBI — SPDR® S&P® Biotech ETF is a US ETF managed by SPDR Series Trust, categorised as United States Small Cap Blend / Core Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: SPDR Series Trust
- Category: United States Small Cap Blend / Core Health Care Equity
- Assets under management: $10.73B
- 1-year return: 91.7%
- Ticker: XBI
- SEC CIK: 0001064642
- SEC series ID: S000010018
- Share class ID: C000027706
XBI Holdings
Top 10 holdings of SPDR® S&P® Biotech ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| State Street Global Advisors | 5.91% |
| Apogee Therapeutics Inc | 1.49% |
| Moderna Inc | 1.41% |
| Twist Bioscience Corp | 1.41% |
| Oruka Therapeutics Inc | 1.38% |
| Kymera Therapeutics Inc | 1.36% |
| Viking Therapeutics Inc | 1.30% |
| Praxis Precision Medicines Inc | 1.29% |
| Erasca Inc | 1.27% |
| Revolution Medicines Inc | 1.20% |
XBI Portfolio Allocation
Asset-class allocation of SPDR® S&P® Biotech ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.9% |
| Cash & Equivalents | 5.9% |
| Derivatives | 0.1% |
XBI Performance
Total returns for XBI (as of 2026-09-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 29.8% |
| 1 year | 91.7% |
| 3 years (annualised) | 24.1% |
| 5 years (annualised) | 3.3% |
XBI Risk Information
Risk metrics for XBI, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 18.3%
XBI Costs and Fees
XBI costs about $35 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.35%
- Gross expense ratio: 0.35%
- Portfolio turnover: 74%
- Brokerage commissions: 1.82 bps of average net assets (SEC N-CEN)
XBI Cashflows
Over the 12 months to 2026-06, SPDR® S&P® Biotech ETF had net inflows of $1.33B, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-06 | $918.67M |
| 2026-05 | −$223.59M |
| 2026-04 | $633.31M |
| 2026-03 | −$589.50M |
| 2026-02 | −$443.25M |
| 2026-01 | $307.41M |
XBI Debt Constituents
No individual debt constituents are reported in SPDR® S&P® Biotech ETF's latest SEC N-PORT filing.
XBI Prospectus and SEC Filings
Official SPDR® S&P® Biotech ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2025-10-24
- Prospectus (485BPOS) — filed 2024-10-24
- Prospectus supplement (497) — filed 2024-11-01
- Portfolio holdings (N-PORT) — filed 2026-08-28
- Portfolio holdings (N-PORT) — filed 2026-05-28
- Portfolio holdings (N-PORT) — filed 2026-02-26
- Annual census (N-CEN) — filed 2026-09-11
- Annual census (N-CEN) — filed 2025-09-12
Related Funds
Other United States Small Cap Blend / Core Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.